Cantor Fitzgerald analyst Louise Chen last night downgraded Aclaris Therapeutics to Neutral from Overweight without a price target after the company announced that zunsemetinib did not meet the primary or secondary efficacy endpoints for its rheumatoid arthritis study. The firm is moving to the sidelines until the company’s go-forward strategy becomes more clear.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACRS:
- Aclaris Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Aclaris Therapeutics price target lowered to $8 from $29 at BTIG
- Aclaris Therapeutics downgraded to Market Perform from Outperform at Leerink
- Aclaris Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Aclaris Therapeutics downgraded to Hold from Buy at Stifel